Xvivo Perfusion AB 

$6.54
6
+$0+0% Wednesday 21:00

Statistics

Day High
6.54
Day Low
6.54
52W High
8.74
52W Low
4.25
Volume
100
Avg. Volume
315
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.04
0.06
0.17
0.27
Expected EPS
0.0682122
Actual EPS
N/A

Financials

2.05%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
236.82MRevenue
4.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XVIPY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.33B
Medtronic offers products for cardiac and vascular surgeries, competing in the organ preservation segment.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific competes in the medical devices sector, including technologies for less invasive surgeries.
Stryker
SYK
Mkt Cap136.19B
Stryker provides medical devices for various surgeries, indirectly competing in the organ transplant space.
Intuitive Surgical
ISRG
Mkt Cap189.4B
Intuitive Surgical's robotic-assisted surgical systems can be used in transplant surgeries, offering an alternative to traditional methods.
Edwards Lifesciences
EW
Mkt Cap48.41B
Edwards Lifesciences specializes in heart valves and hemodynamic monitoring, competing in the cardiovascular market.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers medical devices, diagnostics, and nutrition products that serve similar patient groups as XVIVO.
Baxter International
BAX
Mkt Cap9.49B
Baxter International provides a range of hospital and renal products, including organ preservation solutions.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc. competes in the musculoskeletal healthcare sector, including products that can be used in transplant surgeries.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson's medical devices segment offers products that can be used in various surgeries, including organ transplants.
Danaher
DHR
Mkt Cap152.13B
Danaher Corporation's life sciences and diagnostics segments offer products that can be used in the organ transplant process.

About

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Show more...
CEO
Mr. Christoffer Rosenblad
Employees
170
Country
US
ISIN
US98390P1066

Listings

0 Comments

Share your thoughts

FAQ

What is Xvivo Perfusion AB stock price today?
The current price of XVIPY is $6.54 USD — it has increased by +0% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
What is Xvivo Perfusion AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xvivo Perfusion AB stocks are traded under the ticker XVIPY.
When is the next Xvivo Perfusion AB earnings date?
Xvivo Perfusion AB is going to release the next earnings report on April 24, 2026.
What were Xvivo Perfusion AB earnings last quarter?
XVIPY earnings for the last quarter are 0.11 USD per share, whereas the estimation was 0.07 USD resulting in a +52.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xvivo Perfusion AB revenue for the last year?
Xvivo Perfusion AB revenue for the last year amounts to 236.82M USD.
What is Xvivo Perfusion AB net income for the last year?
XVIPY net income for the last year is 4.85M USD.
How many employees does Xvivo Perfusion AB have?
As of April 01, 2026, the company has 170 employees.
When did Xvivo Perfusion AB complete a stock split?
Xvivo Perfusion AB has not had any recent stock splits.
Where is Xvivo Perfusion AB headquartered?
Xvivo Perfusion AB is headquartered in Mölndal, US.